Insulin resistance-reducing effect of a new thiazolidinedione derivative, pioglitazone.

DOI Web Site Web Site PubMed 2 Citations 47 References
  • IKEDA Hitoshi
    Takeda Chemical Industries, Ltd., Pharmaceutical Research Division
  • SUGIYAMA Yasuo
    Takeda Chemical Industries, Ltd., Pharmaceutical Research Division

Bibliographic Information

Other Title
  • ピオグリタゾンのインスリン抵抗性改善作用
  • 新薬紹介総説 ピオグリタゾンのインスリン抵抗性改善作用
  • シンヤク ショウカイ ソウセツ ピオグリタゾン ノ インスリン テイコウセイ カイゼン サヨウ

Search this article

Description

Takeda has a relatively long history in diabetes research. Pioglitazone, a thiazolidinedione derivative, was developed from our basic research on diabetic animal models in the 1960s and our chemical research on lipid-lowering agents in the 1970s. Pioglitazone reduced plasma glucose, triglyceride and insulin levels in obese-diabetic animal models with insulin resistance in liver and/or peripheral tissues, but did not decrease normoglycemia in normal rats and aged dogs or hyperglycemia in insulin-deficient streptozocininduced diabetic rats and impaired-insulin-secretory Goto-Kakizaki rats. The ED50 of plasma glucoselowering action was 0.5 mg/kg/day in Wistar fatty rats. These findings clearly indicate that pioglitazone works in animals with insulin resistance and has a quite different mechanism from sulfonylureas and insulin itself. Although the exact mechanism of pioglitazone still remains obscure, pioglitazone normalized abnormalities in the cellular signal transduction of insulin. These effects seem to be due to the inhibitory action of pioglitazone on TNF-α production, which is one of the factors responsible for insulin resistance. Pioglitazone is a potent agonist for the peroxisome proliferator-activated receptor, (PPAR)-γ, that is related to differentiation of adipocytes, and the relationship between TNF-α production and PPAR-γ has been reported. Therefore, the agonistic activity of pioglitazone on PPAR-γ may be involved in the mechanism of reduction of insulin resistance. The clinical data clearly demonstrated that pioglitazone, at clinical doses of 15-45 mg/day, decreased plasma glucose, HbA1c and triglyceride, increased plasma HDL-cholesterol, but did not alter total cholesterol and LDL-cholesterol levels. These findings suggest that pioglitazone has a benefit for prevention of cardiovascular diseases in addition to diabetic complications.

Journal

Citations (2)*help

See more

References(47)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top